The transition to testing investigational drugs in populations lacking overt functional impairment necessitates a departure from traditional assessment models. Researchers must now navigate the variability of early-stage manifestations by implementing novel cognitive batteries and digital analytics. This evolution in trial design requires that operational execution, particularly regarding rater selection and monitoring, remains as rigorous as the underlying scientific hypothesis to prevent the loss of critical data signals.
In section Releases
Optimizing Data Integrity in Early-Stage Alzheimer’s Clinical Trials
As clinical research shifts toward identifying Alzheimer’s disease at its earliest, asymptomatic stages, the challenge of capturing subtle cognitive changes grows. Industry experts are convening to address how refined scientific strategies, specialized rater training, and flexible eCOA technologies can safeguard endpoint reliability in increasingly complex global study environments.
On July 9, 2026, a panel of experts from Clinical ink and Cogstate will explore these technical requirements in an upcoming webinar. The discussion will focus on the alignment of endpoint strategy with digital delivery methods, including BYOD and provisioned device support. Participants will examine how these tools enable real-time data visibility, ensuring that studies remain robust even when conducted across decentralized, global sites. The session features Scott Neff, David Anderson, and Megan Petrylak of Clinical ink, alongside Dr. Edward I. Bartolic of Cogstate, who will provide actionable frameworks for maintaining regulatory readiness throughout the trial lifecycle.
Comments (0)
No comments yet. Be the first!